

Page 9, line 18, delete "Sn" and insert therefor --56--.

Page 10, line 2, after "followed by rest of therapy on day," delete "1" and insert --2--.

Page 14, lines 8 and 18, delete "Rituximab®" and insert therefor at each occurrence
--RITUXAN®--.

Page 15, last line, delete "Rituximab®" and insert therefor --RITUXAN®--.

Page 15, line 13, delete "http://www.cancernetwork.com" and insert therefor --See

O'Brien et al. (1996) Ann. Oncol. 7 Suppl. 6: S27-33; and Keating et al.

(1994) Drugs 47 Suppl. 6: 39-49, (1993) Semin. Oncol. 20 (5 Suppl. 7): 13-20,

and (1988) Nouv. Rev. Fr. Hematol. 30 (5-6): 461-6--.

Page 16, lines 4, 5, 8 (both occurrences), 9, 12 and 13, delete "Rituximab®" and
insert therefor at each occurrence --RITUXAN®--.

IN THE CLAIMS:

Please amend Claims 1, 8, 11 and 12 as follows:

1. (Amended) A method of treating a hematologic malignancy associated with high numbers of circulating tumor cells by administering a therapeutically effective amount of an anti-CD20 antibody or antigen-binding fragment thereof, said amount being effective to achieve a reduction in circulating tumor cells.

8. (Amended) The method of Claim 3, wherein said antibody is administered in combination with at least one treatment selected from the group consisting of radiation, chemotherapy, [and/or] and lymphokine administration, and wherein said lymphokine administration serves to upregulate the expression of CD20 on tumor cells.